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Abstract
Sheldon-Hall syndrome (SHS) is a rare multiple congenital contracture syndrome characterized by
contractures of the distal joints of the limbs, triangular face, downslanting palpebral fissures, small
mouth, and high arched palate. Epidemiological data for the prevalence of SHS are not available, but
less than 100 cases have been reported in the literature. Other common clinical features of SHS
include prominent nasolabial folds, high arched palate, attached earlobes, mild cervical webbing,
short stature, severe camptodactyly, ulnar deviation, and vertical talus and/or talipes equinovarus.
Typically, the contractures are most severe at birth and non-progressive. SHS is inherited in an
autosomal dominant pattern but about half the cases are sporadic. Mutations in either MYH3,
TNNI2, or TNNT3 have been found in about 50% of cases. These genes encode proteins of the
contractile apparatus of fast twitch skeletal muscle fibers. The diagnosis of SHS is based on clinical
criteria. Mutation analysis is useful to distinguish SHS from arthrogryposis syndromes with similar
features (e.g. distal arthrogryposis 1 and Freeman-Sheldon syndrome). Prenatal diagnosis by
ultrasonography is feasible at 18–24 weeks of gestation. If the family history is positive and the
mutation is known in the family, prenatal molecular genetic diagnosis is possible. There is no specific
therapy for SHS. However, patients benefit from early intervention with occupational and physical
therapy, serial casting, and/or surgery. Life expectancy and cognitive abilities are normal.
Disease name and synonyms
Sheldon-Hall syndrome (SHS);
Distal arthrogryposis type 2B (DA2B);
Freeman-Sheldon syndrome variant;
Arthrogryposis multiplex congenita, type II.
Definition
Sheldon-Hall syndrome (SHS, MIM# 601680) or distal
arthrogryposis type 2B (DA2B) is an autosomal dominant
disorder characterized by congenital contractures of the
distal joints of the limbs without a primary neurological
defect. SHS is similar to another distal arthrogryposis
called Freeman-Sheldon syndrome (FSS or DA2A), first
described by Freeman and Sheldon in 1938, but distin-
guished as a separate entity in 1997 [1,2]. The most com-
mon clinical features of SHS include a triangular face,
downslanting palpebral fissures, prominent nasolabial
folds, small mouth, high arched palate, attached earlobes,
mild cervical webbing, short stature, severe camptodac-
tyly, ulnar deviation, and vertical talus and/or talipes
equinovarus [2].
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Epidemiology
The prevalence of arthrogryposis is about 1/3000 [3]. Epi-
demiological data for the distal arthrogryposis (DA) syn-
dromes are not available, but anecdotal data suggest that
SHS is the most common of the DAs and the most fre-
quent cause of heritable arthrogryposis. The prevalence of
DA appears to be similar across different populations
although most of the individuals reported to date are of
European ancestry. There is no known sex bias.
Clinical description
The major clinical features of SHS are summarized in
Table 1. The clinical presentation is highly variable both
within and between families. Still, in most cases the clini-
cal diagnosis of SHS is based on the pattern of contrac-
tures observed at birth, which are usually limited to hands
and feet. Most patients have camptodactyly, ulnar devia-
tion and/or overlapping of the fingers, a narrow and trian-
gular face, and overlapping toes (Figure 1). The
contractures are virtually always worse at birth and non-
progressive.
Facial manifestations
Among the facial characteristics of SHS the most common
finding is a narrow face that is pointed at the chin giving
the face a triangular appearance. High arched palate and
micrognatia are also very common. Down slanting palpe-
bral fissures are seen in some individuals. Other facial
findings include small mouth, high nasal bridge, promi-
nent nasolabial folds, bulbous nose, malar hypoplasia,
facial asymmetry, hypertelorism, and posteriorly angu-
lated ears or some other ear abnormalities [4]. Overall
facial movement may be diminished.
Limbs
In an isolated case, the presence of congenital contractures
is mandatory in order to entertain the diagnosis of SHS.
The joints of the hands, wrists, feet, and ankles are most
commonly involved although more proximal joints (e.g.,
elbow, shoulder, knee, and hip) also can be affected. Con-
tractures of the upper limbs typically manifest as overlap-
ping fingers, camptodactyly, and ulnar deviation. Talipes
equinovarus, valgus abnormalities, overlapping toes, ver-
tical talus, and tarsal fusion are the most common find-
ings in the lower limbs. The severity of contractures can
vary substantially between upper and lower limbs, and
the left and right sides of the body. An affected individual
might have both equinovarus and calcaneovalgus abnor-
malities in his/her feet. Contractures are most severe at
birth and non-progressive. However, flexion contractures
can worsen over time in the absence of appropriate inter-
vention (e.g., occupational therapy, physical therapy, sur-
gery).
Growth and development
Growth parameters during the prenatal and perinatal peri-
ods are usually within the range of normal. Gross and fine
motor milestones may be achieved somewhat later than
age-matched controls but virtually all affected individuals
become ambulatory without assist devices. Speech and
language are rarely delayed. Cognitive abilities are usually
not affected. Life expectancy is normal.
Other clinical features
Scoliosis, developmental dysplasia of the hips, and short
or webbed neck have been reported in some patients [4].
Etiopathogenesis
SHS is transmitted as an autosomal dominant trait. Famil-
ial recurrence has been reported for approximately half of
the cases [5].
SHS is caused by mutations in the genes that encode fast
twitch skeletal muscle isoforms of troponin I (TNNI2)
and troponin T (TNNT3), and embryonic myosin
(MYH3) [5-7]. Mutations in these genes explain approxi-
mately half of cases studied to date. The remaining cases
could be explained by mutations in regulatory regions of
TNNI2, TNNT3, or MYH3, large deletions of these genes,
or mutations in other as of yet unidentified genes.
The fast twitch skeletal muscle troponin I is encoded by
the TNNI2 gene which is located on the short arm of chro-
mosome 11 (11p15.5). Troponins are muscle proteins
that are part of the contractile apparatus. To date, 4 differ-
ent  TNNI2  mutations have been reported in DA2B
patients: p.R156X, p.R174Q, p.E167del, and p.K175del
[6-10]. All of these mutations have been found in familial
cases. p.R156X and p.K175del were each found in 2 fam-
ilies, p.R174Q was reported in 4 families, and p.E167del
in a single family. All of the reported mutations map to
the C-terminal region of troponin I which is required for
the inhibitory action of the protein [6]. The mechanism
by which mutations in TNNI2  cause contractures is
unclear but troponin I binds to actin and tropomyosin,
and in the absence of Ca2+ prevents muscle contraction. In
vitro and ex vivo contractility studies of troponin I
mutants suggest that p.R156X and p.R174Q increase mus-
cle contractility via increasing Ca2+ sensitivity [11] sug-
gesting that these mutations disturb troponin I's ability to
regulate Ca2+ levels.
The TNNT3 gene, which is near TNNI2 on chromosome
11p15.5, was considered a positional and functional can-
didate [7]. It encodes the fast-twitch skeletal muscle iso-
form of troponin T and like troponin I forms part of the
contractile apparatus of fast twitch myofibers. A missenseOrphanet Journal of Rare Diseases 2009, 4:11 http://www.ojrd.com/content/4/1/11
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mutation predicted to cause substitution of an arginine
residue with histidine (p.R63H) was found in a mother
and her 2 affected children [7]. This mutation maps to a
domain of the protein that is not involved in direct inter-
actions with other troponins, but it causes increased
ATPase activity and Ca2+-dependent force generation [11].
Hence, p.R63H appears to also increase muscle contractil-
ity.
After it became evident that SHS was caused by defects of
the contractile apparatus of fast-twitch myofibers, we
investigated whether SHS could be caused by mutations
in genes that encode other proteins of the contractile
apparatus [5]. The genes encoding myosin heavy chains,
the major component of the contractile unit, were
screened in patients in whom no mutation had been
found in TNNI2  or  TNNT3, giving priority to genes
expressed during prenatal or perinatal development. This
eventually led to the screening of the gene that encodes
embryonic myosin heavy chain (MYH3). Mutations in
MYH3 were found in 5 of 12 familial (42%) and 7 of 26
sporadic (27%) cases [5]. All but one of these were mis-
sense mutations. A p.841del mutation was found in one
familial and one sporadic case. Seven missense mutations
(p.S261F, p.S292C, p.E375K, p.D517Y, p.G769V, and
p.T178I) were located in the region of MYH3 that encodes
the head domain of myosin; and two (p.D1622A,
p.A1637V) were located in the region that encodes the tail
domain. One missense mutation (p.K838E) and the dele-
tion (p.841del) were predicted to disrupt the linker region
between the head and the tail domains of MYH3. All of
the MYH3 mutations were predicted to affect the forma-
tion and stability of the contractile apparatus. Collec-
tively, mutations in the MYH3, TNNI2, and TNNT3 genes
account for about half of all studied cases of SHS.
Genotype-phenotype relationship
Extensive within and between family phenotypic varia-
tion is observed in SHS. Both the specific joints affected
and the degree to which joints are affected varies. The
basis of this variability is unclear but could arise by several
different mechanisms or a combination thereof as none
are mutually exclusive. First, mutation in different genes
could cause different phenotypes. However, none of the
phenotypic variability between families appears to corre-
spond to disruption of specific proteins much less specific
genotypes. In other words, individuals with a mutation in
either TNNI2, TNNT3, or MYH3 have phenotypes that
cannot be distinguished from one another. Even individ-
uals with the same mutation exhibit widely variable clini-
cal findings. Nevertheless, an important caveat is that a
relatively small number of cases with any specific muta-
tion have been studied, and the phenotypic information
from many of these cases is incomplete. Overall, more
cases need to be studied to rigorously evaluate if there is a
substantial correspondence between genotype and phe-
notype in individuals with SHS.
MYH3 mutations that cause SHS are distinct from those
that cause FSS [5]. Almost all FSS mutations are predicted
to affect a pocket of embryonic myosin which is impor-
tant in ATP binding and hydrolysis whereas mutations
that cause SHS disturb amino acid residues on the surface
of embryonic myosin. Therefore, it is reasonable to
hypothesize that FSS is caused by defective kinase action,
while SHS is caused by the instability of the protein com-
plex.
Diagnosis
The diagnosis of SHS is based on clinical characteristics
[2,4]. The major diagnostic criteria for SHS are ulnar devi-
ation, camptodactyly, overriding fingers, hypoplastic and/
or absent flexion creases, talipes equinovarus, calcaneo-
valgus abnormalities, vertical talus and/or metatarsus
Clinical features of Sheldon-Hall syndrome Figure 1
Clinical features of Sheldon-Hall syndrome. Note the 
pointed chin, long philtrum, prominent nasolabial folds, 
downslanted palpebral fissures, attached ear lobes. She also 
has camptodactyly and ulnar deviation at the wrist. The right 
foot was casted to treat talipes equinovarus.Orphanet Journal of Rare Diseases 2009, 4:11 http://www.ojrd.com/content/4/1/11
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varus [2]. Minor diagnostic criteria include a triangular
face, downslanting palpebral fissures, attached ear lob-
ules, a small mouth, a small mandible, an arched palate,
cervical webbing and short stature. Exclusion criteria
include primary neurological and muscle abnormalities.
At least 2 of the major diagnostic criteria must be present
in at least one member of a family to be classified as
affected. In the presence of an individual meeting these
criteria inclusion criteria might be relaxed for other family
members. In addition, a positive family history can help
exclude sporadic disorders with similar features. Because
of the phenotypic variability some patients might show
atypical presentations. However, congenital contractures
of the distal joints, a small mouth, prominent nasolabial
folds and a triangular face are consistent findings. The
severity of the contractures typically improves with age
and the facial characteristics are often less distinctive in
adults.
Antenatal diagnosis
Occasionally women may note decreased fetal move-
ments, but they might also be normal. The clinical find-
ings of SHS can be detected prenatally by
ultrasonography. However, detection may not be possible
until 18–24 weeks of gestation. If the family history is pos-
itive and the mutation is known in the family, prenatal
molecular genetic diagnosis is possible [12].
Genetic counseling
SHS is a monogenic disorder with autosomal dominant
inheritance. Affected individuals have a 50% risk of trans-
mitting the disease to their offspring. However, many of
the patients reported to date have had de novo mutations.
The recurrence risk in such families is low but recurrent
"de novo" mutations in several families with DA suggest
that germline mosaicism does occur in DA.
Mutation analysis of the known genes should be offered
to affected individuals in certain circumstances (e.g., diag-
nosis is in question). Since the majority of mutations have
been found in MYH3, this gene should be screened first. If
no mutations are found in MYH3, TNNI2 and TNNT3
genes should also be sequenced.
Differential diagnosis
SHS shares features with DA1 and FSS. DA1 is defined as
the prototypic DA, and the clinical findings are limited to
the contractures of the distal joints of the hands and feet
[13]. Individuals with DA1 do not have major contrac-
tures of the facial muscles or facial abnormalities [13].
In SHS the shape of the mouth and chin is different from
that of FSS [2,4]. Generally, the facial contractures are not
as severe in SHS. Newborns affected with SHS do not have
the pinched lips accompanied by the appearance of a
"whistling face" nor do they typically have "H" shaped
dimpling of the chin. Feeding difficulties at birth and a
need for surgical revision of the mouth, which are nearly
universal features of children with FSS, are not observed in
SHS. The chin is more triangular in individuals affected
with SHS. In addition, strabismus and severe scoliosis is
less common in SHS than in FSS.
The small mouth may also resemble DA7 (also known as
Trismus-Pseudocamptodactyly syndrome), however, SHS
does not include trismus of the jaw, which is a unique
characteristic of DA7.
Management
There is no specific treatment for SHS. The contractures
occur early in development and they improve postnatally.
Although some spontaneous improvement might be
expected, prolonged use of braces and casts, or multiple
surgeries to correct the limb contractures are often
required. Most patients will benefit from physical therapy,
which should start soon after birth.
Individuals with SHS have a normal life expectancy. Hear-
ing, vision, speech, and motor development should be
checked as appropriate. The majority of the patients will




Small, pointed chin +++
Micrognatia +++
Down-slanting palpebral fissures +++
Prominent nasolabial folds +++
High arched palate ++
Long philtrum ++
Long face +
Attached ear lobes +
Cleft lip/palate +
Limbs
Ulnar deviation of fingers +++
Clasped thumb +++
Overlapping fingers +++










Developmental dysplasia of the hip ++
Short neck +
Webbed neck +Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Orphanet Journal of Rare Diseases 2009, 4:11 http://www.ojrd.com/content/4/1/11
Page 5 of 5
(page number not for citation purposes)
require series of orthodontic treatment as well as pro-
longed orthopedic management. Surgical procedures can
be complicated by difficult intravenous access, laringos-
copy, and spinal anesthesia. In addition, there is evidence
to suggest that individuals with DA syndromes including
SHS are at higher risk for malignant hyperthermia [14].
Unresolved questions
Almost 50% of the patients affected with SHS, do not have
mutations in MYH3, TNNI2, or TNNT3 genes. It needs to
be addressed whether these patients have mutations in
another gene or mutations in regulatory regions of these
genes. With respect to the latter, there are no known fam-
ilies that map to any of the known loci and in whom
mutations have not been identified. The molecular mech-
anism underlying the contractures is not well understood.
Some mutations appear to increase contractility, although
this has not yet been confirmed in ex vivo studies of
myofiber contractility in affected individuals. Finally, the
SHS phenotype starts to develop in utero, suggesting that a
clear understanding of how muscle development is per-
turbed in SHS will require studies in animal models.
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